Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment
BOSTON, Nov. 12, 2025 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA) shareholder Heng Ren Silk Road Investments LLC today announced that it has heard from more than 100 independent Sinovac shareholders expressing overwhelming support for the immediate payment of a $19.00 dividend previously declared by the board. Sinovac's stock has been halted from trading since 2019. As a result, Sinovac shareholders missed out on an extraordinary windfall from the success of its COVID-19 vaccine, CoronaVac,...
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast cancer (mTNBC) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)....
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. and Europe was the driver of this strong performance. United States: DKK 9,955 million (+22% CER; +19% DKK) Europe: DKK 4,318 million (+13% CER; +13%...
Mabwell’s Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate a Phase II clinical trial for pathological scarring. 9MW3811 becomes the world's first IL‑11‑targeting therapeutic to enter clinical stage for this indication....
Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is based on a strong mutual consensus: Sanyou Bio possesses profound expertise in innovative biopharmaceutical discovery and development,...
From Bangkok to the World: Aura Bangkok Clinic Showcases International Standards in Aesthetic Care
BANGKOK, Nov. 11, 2025 /PRNewswire/ -- Aura Bangkok Clinic, a leader in Thailand's medical aesthetic industry, is enhancing the country's reputation as a top destination for Thai beauty medical tourism through its global expertise, award-winning services, and internationally recognized training programs. Attracting international patients seeking safe, natural, and cost-effective treatments, the company continues to set benchmarks in patient care,...
The Sigourney Award-2025 Celebrates Four Recipients Honored for Creative Trailblazing Work Expanding Psychoanalytic Thought Globally
Interdisciplinary Work from Israel, Uruguay, and the United States Earns The Prestigious Sigourney Award-2025 Prize SAN FRANCISCO, Nov. 11, 2025 /PRNewswire/ -- The trailblazing work of four recipients has won The Sigourney Award-2025, earning international recognition and a substantial cash prize for advancing psychoanalytic thought and principles throughout the world. Announced today by...
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI...
Coreline Soft Selected as Exclusive AI Provider for France’s National Lung Cancer Screening Pilot Project, IMPULSION
- APHP-led IMPULSION project secures Coreline Soft as sole AI supplier- UGAP (France's central public procurement agency) registration completed, opening opportunities with France's largest public hospitals SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ -- Coreline Soft, a global leader in AI-powered chest diagnostic solutions, today announced its selection as the exclusive artificial intelligence supplier for IMPULSION, the French nationwide lung...
Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software
Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS). Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1 Delivers near-universal detection of an expansive range of analytes across pharmaceutical formulations, food additives, and environmental pollutants, including those that are...
